ArticleFrontiers in digital health2026
Analysis of intellectual property strategies across different categories of digital therapeutics.
Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in digital technology and the coronavirus disease (COVID-19) pandemic have accelerated the digital transformation of healthcare. Digital therapeutics (DTx), which deliver evidence-based interventions through digital means to treat or prevent diseases, are expected to generate significant value in modern healthcare. Strategic intellectual property (IP) protection for DTx is essential to support development costs, including clinical trials, and to ensure sustainable innovation. This study analyzed patent and design right strategies across different categories of DTx. We examined 25 DTx products registered with the Digital Therapeutics Alliance in the United States and five U.S. Food and Drug Administration-approved augmented and virtual reality products as of April 2023, classifying them into three categories: app-based, app + device-based, and entertainment-based DTx. Patent data were collected from the Derwent Innovation Index, and design rights were identified using the Patent Public Search. A case study of one representative product from each category was conducted to contextualize these findings. The results revealed that half of app-based DTx lacked patent applications, often relying on platform technologies, while all app + device-based DTx had patents covering programs, biometric acquisition, and platform technology. Entertainment-based DTx exhibited the highest average number of patent applications, possibly due to their novelty and divergence from conventional treatments. Only five of the 30 products were protected by design rights, which appeared limited in scope and practical utility. Overall, distinct differences in patenting approaches were observed among DTx types, with design rights used sparingly. These findings suggest that optimal IP strategies vary by product architecture and that understanding such distinctions is essential for promoting innovation in digital therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.